Ads
related to: non alcoholic fatty liver medication fda approval update- About NASH
Learn more about the consequences
of NASH and patient management.
- NASH With Fibrosis
Learn about the basics of NASH
on the official HCP website.
- NASH Identification
Find more on the identification
and monitoring.
- Learn More Today
Explore NASH, uncover the risks,
and stay informed.
- About NASH
Search results
Results from the WOW.Com Content Network
(Reuters) -The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition ...
(Reuters) -Madrigal Pharmaceuticals shares jumped as much as 23% on Friday after its oral drug became the first approved treatment for a fatty liver disease known as non-alcoholic steatohepatitis ...
The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday.. NASH — also ...
Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. [1] It is a thyroid hormone receptor beta (NR1A2) agonist. [1] The most common side effects include diarrhea and nausea. [2] Resmetirom was approved for medical use in the United States in March 2024. [2] [3] [4]
Non-alcoholic steatohepatitis is a common cause of abnormal liver function with histological features of fatty liver, inflammation and fibrosis. It may progress to cirrhosis and is becoming an increasing indication for liver transplantation. It is increasing in prevalence. OCA is proposed to treat NASH. [21]
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. [1] [2] [3] [4]
In March 2024, the U.S. Food and Drug Administration (FDA) approved resmetirom — sold under the brand name Rezdiffra® — for people with NASH and moderate to advanced liver scarring.
The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as non-alcoholic fatty liver disease, polycystic ovary syndrome, and diseases of the reward system such as addictions.
Ads
related to: non alcoholic fatty liver medication fda approval update